{"gene":"PBX3","run_date":"2026-06-10T05:19:53","timeline":{"discoveries":[{"year":1991,"finding":"PBX3 is a TALE-class homeodomain transcription factor with 94% identity to PBX1 over 266 amino acids spanning and flanking the homeodomain. PBX3 mRNA is alternatively spliced to yield two translation products with different carboxy termini, a feature shared with PBX1 but not PBX2.","method":"Molecular cloning, sequence analysis, Northern blot (alternative splicing)","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — primary molecular characterization with sequence analysis and alternative splicing demonstrated directly; foundational paper replicated across subsequent literature","pmids":["1682799"],"is_preprint":false},{"year":2004,"finding":"Pbx3-deficient mice die within hours of birth from central respiratory failure due to abnormal inspiratory neuron activity in the medulla oblongata. Pbx3 forms a DNA-binding complex with the metaHox transcription factor Rnx (Tlx3), and in the absence of Pbx3, Rnx's ability to enhance transcription in vitro as part of a TALE-protein complex is abolished, though Rnx expression itself is unaffected.","method":"Knockout mouse (Pbx3-deficient), in vitro transcription assay, co-immunoprecipitation / DNA-binding complex formation","journal":"The American journal of pathology","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function mouse model with defined respiratory phenotype plus in vitro transcriptional assay demonstrating Pbx3-dependent Rnx activity; multiple orthogonal methods","pmids":["15466398"],"is_preprint":false},{"year":2001,"finding":"Two novel PBX3 isoforms (PBX3C and PBX3D) generated by alternative splicing are unable to interact with the PBX-interacting factor PREP1 and interact only weakly with MEIS proteins, in contrast to canonical PBX3A/B isoforms. PBX3C expression is favored in leukemia cells whereas PBX3D predominates in normal cells.","method":"RT-PCR (isoform identification), co-immunoprecipitation / interaction assays (functional binding studies)","journal":"Genes, chromosomes & cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding assays showing differential interaction specificity of isoforms; single lab, two methods","pmids":["11579467"],"is_preprint":false},{"year":2004,"finding":"Retinoic acid increases PBX3 mRNA levels as a secondary (not primary) transcriptional response requiring new protein synthesis, and retinoic acid treatment also significantly extends PBX3 protein half-life. PBX proteins associate with RA-dependent increased MEIS protein levels, and RA may decrease proteasome-dependent PBX protein degradation.","method":"P19 cell differentiation model, cycloheximide chase (mRNA stability), protein half-life assay, co-immunoprecipitation with MEIS proteins","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct measurement of mRNA stability and protein half-life, plus co-IP with MEIS; single lab, multiple orthogonal methods","pmids":["15095411"],"is_preprint":false},{"year":2007,"finding":"Conditional loss of Pbx3 caudal to the hindbrain leads to progressive locomotion and posture deficits, reduced dorsal horn size, and loss of calbindin-, PKC-gamma-, and calretinin-expressing neurons in laminae I–III. In embryonic dorsal horn, Pbx3 is expressed in a subset of glutamatergic neurons; its absence causes incorrect specification of some glutamatergic neurons and abnormal positioning of Meis+ glutamatergic neurons.","method":"Conditional knockout mouse, immunohistochemistry, cell counting, neuroanatomical analysis","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with detailed cellular phenotype and neuronal specification defects characterized by multiple markers","pmids":["18155191"],"is_preprint":false},{"year":2012,"finding":"PBX3 (but not PBX1 or PBX2) acts as a critical cofactor of HOXA9 in leukemogenesis: shRNA depletion of Pbx3 significantly inhibits MLL-fusion-mediated cell transformation, and co-expression of PBX3 with HOXA9 synergistically promotes cell transformation in vitro and AML in vivo. The small peptide HXR9, which disrupts HOX-PBX interactions, selectively kills leukemic cells with HOXA/PBX3 overexpression.","method":"shRNA knockdown, retroviral overexpression, in vitro transformation assay, mouse leukemia model, HXR9 peptide treatment","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (KD, OE, in vivo, peptide disruption); replicated in subsequent studies","pmids":["23264595"],"is_preprint":false},{"year":2015,"finding":"Pbx3 and Meis1 must dimerize to support Hox-induced leukemia. In the absence of Pbx3, Meis1 protein is highly unstable and undergoes ubiquitin-proteasome-mediated degradation via a motif coinciding with the Pbx-binding domain; binding to Pbx3 or deletion of this motif prolongs Meis1 half-life. Additionally, Pbx3 overexpression induces endogenous Meis1 transcription. Meis1 binding to Pbx3 is required to form high-affinity DNA/Hoxa9/Meis1/Pbx3 complexes in vitro.","method":"Deletion analysis, co-immunoprecipitation, ubiquitin-proteasome inhibitor assay (MG132), protein half-life measurement, in vitro DNA-binding complex formation, colony-forming assay, transplantation assay","journal":"Haematologica","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — mechanistic dissection of Meis1 stability via Pbx3 binding with reconstituted DNA complex and multiple biochemical and functional methods","pmids":["25911551"],"is_preprint":false},{"year":2015,"finding":"PBX3 is targeted synergistically by let-7c, miR-200b, miR-222, and miR-424 at its 3'-UTR, and is both sufficient and necessary for the acquisition and maintenance of HCC tumor-initiating cell (TIC) properties. PBX3 drives a transcriptional programme activating CACNA2D1, EpCAM, SOX2, and NOTCH3 expression in HCC TICs.","method":"miRNA overexpression/inhibition, luciferase 3'-UTR reporter assay, shRNA knockdown, TIC functional assays (sphere formation, tumorigenicity), rescue experiments, gene expression profiling","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple miRNA validated by luciferase assay, functional necessity shown by KD and rescue, transcriptional targets identified; single lab but multiple orthogonal methods","pmids":["26420065"],"is_preprint":false},{"year":2016,"finding":"Co-expression of PBX3 and MEIS1 (without ectopic HOX) is sufficient to transform normal mouse hematopoietic stem/progenitor cells and cause AML in vivo. PBX3/MEIS1 overexpression recapitulates the MLL-fusion core transcriptome including upregulation of endogenous Hoxa genes. Disruption of the MEIS1-PBX3 binding interface abolishes transformation and HOX gene upregulation.","method":"Retroviral co-expression, in vitro transformation assay, mouse AML model, gene expression profiling, binding-interface disruption mutants","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vitro transformation plus in vivo AML with transcriptomic validation and mechanistic disruption of PBX3/MEIS1 interaction; multiple orthogonal methods","pmids":["26747896"],"is_preprint":false},{"year":2014,"finding":"PBX3 promotes migration and invasion of colorectal cancer cells partially through activation of the MAPK/ERK signaling pathway, as evidenced by upregulation of phosphorylated ERK1/2 upon PBX3 overexpression.","method":"Forced expression and shRNA knockdown, wound-healing assay, Boyden chamber assay, Western blot (p-ERK1/2)","journal":"World journal of gastroenterology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct KD/OE with defined signaling readout (p-ERK1/2); single lab, two orthogonal functional and biochemical methods","pmids":["25561793"],"is_preprint":false},{"year":2016,"finding":"PBX3 promotes gastric cancer invasion and metastasis by inducing EMT (increased N-cadherin and vimentin, decreased E-cadherin) and activating AKT (increased p-AKT Ser473) and MMP-9 activity.","method":"Overexpression/knockdown, Western blot (EMT markers, p-AKT), gelatin zymography (MMP-9), nude mouse xenograft","journal":"Oncology letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple downstream pathway readouts (EMT, AKT, MMP-9) in gain- and loss-of-function experiments; single lab","pmids":["27900025"],"is_preprint":false},{"year":2017,"finding":"Pbx3 deletion via CRISPR/Cas9 in MLL-AF9 AML mouse model significantly prolongs survival and decreases leukemia burden by reducing leukemia stem cell (LSC) capacity and promoting LSC apoptosis. ChIP-seq/qPCR in MLL-rearranged mouse models revealed aberrant epigenetic modifications with increased H3K79me2 and decreased H3K9me3 and H3K27me3 at Pbx3 loci in LSCs.","method":"CRISPR/Cas9 deletion, mouse AML model transplantation, flow cytometry (LSC analysis), ChIP-seq/qPCR (histone modifications)","journal":"International journal of cancer","confidence":"High","confidence_rationale":"Tier 2 / Strong — CRISPR KO with defined LSC phenotype plus epigenomic profiling; multiple orthogonal methods","pmids":["28411381"],"is_preprint":false},{"year":2018,"finding":"PBX3 expression in colorectal cancer is induced by WNT pathway activation and by EMT transcription factors SNAIL and ZEB1, with these effects mediated indirectly through microRNA miR-200. PBX3 is required for a full EMT phenotype in colon cancer cells.","method":"Reporter assays, transcriptomic analysis, miRNA manipulation, siRNA knockdown, in situ hybridization","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis experiments placing PBX3 downstream of WNT/SNAIL/ZEB1 via miR-200, with functional EMT phenotype; single lab","pmids":["29391352"],"is_preprint":false},{"year":2018,"finding":"PBX3 promotes GBM mesenchymal transition through activation of MEK/ERK1/2 signaling, leading to increased c-Myc-dependent LIN28 expression. LIN28 then inhibits let-7b biogenesis; let-7b suppresses PBX3 by targeting its 3'-UTR, forming a positive feedback loop. ChIP experiments confirmed PBX3-driven transcriptional activation of LIN28 via MEK/ERK/c-Myc.","method":"Western blot, ChIP, dual-luciferase reporter assay, shRNA/overexpression, orthotopic mouse model, TGFβ stimulation","journal":"Journal of experimental & clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus luciferase plus rescue experiments in single lab demonstrating feedback loop mechanism","pmids":["30016974"],"is_preprint":false},{"year":2021,"finding":"PBX3 binds to the p53 promoter and suppresses its transcriptional activity, thereby reducing p21 expression and enabling tumor cell proliferation. PBX3 silencing induces p21 expression and increases apoptosis in colorectal cancer cells.","method":"ChIP (PBX3 binding to p53 promoter), luciferase reporter assay, siRNA knockdown, cell cycle/apoptosis analysis","journal":"Acta pharmacologica Sinica","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus reporter assay plus functional KD readout; single lab, two orthogonal molecular methods","pmids":["33526870"],"is_preprint":false},{"year":2023,"finding":"PBX3 directly binds to the G6PD promoter and activates its transcription, stimulating the pentose phosphate pathway (PPP), enhancing NADPH and nucleotide production, decreasing intracellular ROS, and promoting tumorigenic potential in vitro and in vivo.","method":"ChIP (PBX3 binding to G6PD promoter), luciferase reporter assay, metabolic assays (NADPH, nucleotide, ROS), xenograft model","journal":"International journal of biological sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and reporter assay confirm direct promoter binding, metabolic phenotype confirmed; single lab","pmids":["37781025"],"is_preprint":false},{"year":2025,"finding":"PBX3 directly binds to the HMGCR promoter (-167/-151 region) and increases its transcriptional activity, thereby upregulating cholesterol biosynthesis in HCC cells and enhancing tumorigenic potential in vivo.","method":"ChIP (PBX3 binding to HMGCR promoter), luciferase reporter assay, cholesterol biosynthesis measurement, xenograft model","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and reporter assay confirm direct promoter binding with metabolic and tumor phenotype; single lab","pmids":["40508020"],"is_preprint":false},{"year":2021,"finding":"PBX3 directly binds to the TOP2A promoter to activate its transcription, regulating mast cell DNA damage, senescence, mitochondrial function, and parthanatos in allergic rhinitis. PBX3 knockdown significantly alleviates AR symptoms in mice.","method":"ChIP (PBX3 binding to TOP2A promoter), shRNA knockdown, mouse AR model, mitochondrial membrane potential assay","journal":"iScience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP confirms direct promoter binding with functional mouse model readout; single lab","pmids":["42006311"],"is_preprint":false},{"year":2020,"finding":"lncRNA H19 inhibits CYP1B1 expression by regulating PBX3, which directly binds to the CYP1B1 promoter to control its activity. This H19/PBX3/CYP1B1 axis modulates cardiomyocyte pyroptosis during myocardial infarction.","method":"RIP, dual-luciferase reporter assay (H19-PBX3-CYP1B1 axis), overexpression/knockdown, MI rat model","journal":"Molecular and cellular biochemistry","confidence":"Low","confidence_rationale":"Tier 3 / Weak — reporter assay and RIP in single lab; mechanistic role of PBX3 as transcriptional repressor of CYP1B1 suggested but not confirmed by direct ChIP of PBX3 at CYP1B1 promoter","pmids":["33389498"],"is_preprint":false},{"year":2020,"finding":"PBX3 acts as a transcriptional activator of the lncRNA SNHG10 promoter in gastric cancer cells. SNHG10 in turn stabilizes PBX3 mRNA through recruiting the RNA-binding protein DDX54, forming a positive feedback loop. DDX54 was shown by RIP and RNA pull-down to bind both SNHG10 and PBX3 mRNA.","method":"ChIP (PBX3 binding to SNHG10 promoter), luciferase reporter assay, RIP, RNA pull-down (DDX54-SNHG10-PBX3 mRNA interaction)","journal":"Digestive diseases and sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP, luciferase, RIP, and RNA pull-down in single lab; multiple orthogonal molecular methods","pmids":["32712782"],"is_preprint":false},{"year":2021,"finding":"Leptin activates PBX3 expression in a STAT3-dependent manner in breast cancer cells. PBX3 confers letrozole resistance via transactivation of FGFR1 signaling, and this requires interaction with the MTA1-HDAC2 complex.","method":"Patient-derived xenograft, pharmacological STAT3 inhibition, gain/loss-of-function, microarray profiling, co-immunoprecipitation (PBX3-MTA1-HDAC2 complex)","journal":"Endocrine-related cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — STAT3-dependent regulation and co-IP with MTA1-HDAC2 complex with functional resistance phenotype; single lab, multiple methods","pmids":["33608482"],"is_preprint":false},{"year":2022,"finding":"ATRAP directs USP14-mediated deubiquitination and stabilization of PBX3 protein, preventing its degradation. USF1 transcriptionally activates ATRAP expression, creating a USF1/ATRAP/PBX3 axis that activates AKT/mTOR signaling in breast cancer.","method":"Co-immunoprecipitation (ATRAP-PBX3, USP14-PBX3), ubiquitination assay, protein stability assay, microarray analysis, functional assays","journal":"International journal of biological sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical deubiquitination mechanism with co-IP and functional validation; single lab","pmids":["35414770"],"is_preprint":false},{"year":2024,"finding":"PHAX stabilizes PBX3 mRNA through interaction with LIN28B (RNA-binding protein). PBX3 then directly binds to the TET2 promoter and transcriptionally represses it, promoting esophageal cancer cell proliferation and suppressing apoptosis and autophagy.","method":"Co-immunoprecipitation (PHAX-LIN28B), mRNA stability assay, ChIP (PBX3 at TET2 promoter), luciferase reporter assay, KD/OE functional assays, mouse tumor model","journal":"Cancer science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus ChIP plus reporter with functional mouse model; single lab, multiple orthogonal methods","pmids":["39668567"],"is_preprint":false},{"year":2025,"finding":"PBX3 directly binds a cis-regulatory element (SFE1) within intron 1 of SHH and represses its transcriptional activity in the chick Frontonasal Ectodermal Zone; this is opposite to PBX1, which activates transcription through the same element. Overexpressing PBX3 decreases SHH expression, while reducing PBX3 induces ectopic SHH expression.","method":"RCAS viral overexpression/knockdown in chick embryos, ChIP-seq (PBX3/PBX1 binding), ATAC-seq, luciferase reporter assay, in ovo electroporation of reporter constructs","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — ChIP-seq binding validated by luciferase and in ovo reporter plus gain/loss-of-function with SHH phenotype; multiple orthogonal methods in single study","pmids":["40397886"],"is_preprint":false},{"year":2021,"finding":"P2X7 receptor activation upregulates Pbx3 expression in MLL-rearranged AML cells, and the P2X7-Pbx3 pathway accounts for P2X7's pro-leukemic effects on cell proliferation and leukemia stem cell levels.","method":"shRNA knockdown, mouse AML model, patient-derived xenograft, P2X7 antagonist treatment, nude mouse xenograft","journal":"Haematologica","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacological P2X7 manipulation with defined Pbx3-dependent leukemic phenotype; single lab, multiple in vivo models","pmids":["32165482"],"is_preprint":false},{"year":2022,"finding":"P2X1 phosphorylation at S387 and T389 is required for its leukemia-promoting effects. ATP-P2X1-mediated signaling upregulates PBX3, which transactivates BCAT1 to maintain leukemia-initiating cell (LIC) fates.","method":"P2X1 deletion (mouse AML model), phospho-site mutagenesis, gene expression analysis, ChIP (PBX3 transactivation of BCAT1), P2X1 antagonist treatment","journal":"Leukemia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO, phospho-site mutagenesis, and transcriptional target analysis (BCAT1); single lab","pmids":["36418376"],"is_preprint":false},{"year":2025,"finding":"Pbx3 suppresses type I interferon response genes during MLL-AF9-driven AML progression in vivo. Leukemia progression is associated with Pbx3 upregulation in progenitor cells and downregulation of IFN-response genes; enhancing IFN signaling (IFNα) induces leukemic cell differentiation, and this is partially overcome by Pbx3 activity.","method":"CRISPR-mediated chromosomal translocation (MLL-AF9 model), in vivo leukemia progression assay, IFNα treatment, gene expression analysis","journal":"Cancer gene therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR mouse model with defined transcriptional phenotype (IFN suppression) and IFNα rescue; single lab","pmids":["40108441"],"is_preprint":false},{"year":2018,"finding":"A human PBX3 variant (p.A136V), introduced into the homologous zebrafish pbx4 gene (p.A131V) via CRISPR-Cas9 precise genome editing, acts as a genetic modifier of cardiac morphogenesis: homozygous pbx4 p.A131V zebrafish are viable but the variant enhances the embryonic cardiac defect caused by loss of the Hand2 cardiac specification factor.","method":"CRISPR-Cas9 precision genome editing (single-stranded oligodeoxynucleotide knock-in), zebrafish genetic modifier assay (pbx4 p.A131V × hand2 loss-of-function)","journal":"Disease models & mechanisms","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — rigorous precision genome editing with epistasis readout in zebrafish; single lab, well-controlled functional genetics","pmids":["30355621"],"is_preprint":false},{"year":2014,"finding":"PBX3 differential DNA methylation correlates with PBX3 gene expression in AML patients. In inv(16)/CBFB-MYH11 AML, targeted bisulfite sequencing revealed a hypomethylation pattern associated with genes upregulated in this subtype.","method":"Targeted bisulfite sequencing, 454 bisulfite pyrosequencing, microarray gene expression profiling (correlation of methylation with expression)","journal":"Journal of hematology & oncology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — correlative methylation-expression analysis without functional manipulation of methylation at the PBX3 locus","pmids":["25266220"],"is_preprint":false},{"year":2018,"finding":"Inactivation of PBX3 and HOXA9 by reducing H3K79 methylation (via DOT1L inhibitor EPZ5676) promotes apoptosis in NPM1-mutated (NPMc+) leukemic cells. NPMc+ overexpression increases H3K79me2/me3 at the HOXA9 gene locus (but not the PBX3 locus); PBX3 expression is positively regulated by HOXA9; and reduction of either PBX3 or HOXA9 causes NPMc+ cell apoptosis.","method":"ChIP-seq (H3K79 methylation at HOXA9/PBX3 loci), siRNA knockdown, DOT1L inhibitor (EPZ5676) treatment, NPMc+ overexpression/depletion, apoptosis assay","journal":"Theranostics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq with pharmacological and genetic validation; single lab, multiple methods","pmids":["30214626"],"is_preprint":false},{"year":2022,"finding":"PBX3 acts as a transcriptional activator of the lncRNA DLG1-AS1 in triple-negative breast cancer (TNBC) cells, as demonstrated by ChIP assay showing PBX3 binding to the DLG1-AS1 promoter.","method":"ChIP (PBX3 at DLG1-AS1 promoter), luciferase reporter assay, functional TNBC cell assays","journal":"Molecular therapy oncolytics","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, ChIP only without mutagenesis or reconstitution","pmids":["35592389"],"is_preprint":false},{"year":2025,"finding":"METTL3 promotes m6A modification of PBX3 mRNA, leading to its upregulation. PBX3 in turn binds the CA9 promoter and activates its transcription, suppressing ferroptosis in esophageal squamous cell carcinoma.","method":"MeRIP assay (m6A on PBX3 mRNA), ChIP (PBX3 at CA9 promoter), luciferase reporter assay, ferroptosis assays (ROS, MDA, Fe2+), KD/OE functional assays, xenograft","journal":"Pathology, research and practice","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — MeRIP plus ChIP plus reporter assay with functional ferroptosis phenotype; single lab, multiple methods","pmids":["40048803"],"is_preprint":false}],"current_model":"PBX3 is a TALE-class homeodomain transcription factor that forms hetero-oligomeric DNA-binding complexes with HOX proteins (especially HOXA9), MEIS1, and other homeodomain partners to regulate developmental gene expression and oncogenic transcriptional programmes; it directly binds promoters of target genes (SHH, G6PD, HMGCR, TOP2A, p53, TET2, CA9) to activate or repress transcription, stabilizes partner proteins (e.g., MEIS1 via preventing ubiquitin-proteasome degradation), and is itself post-transcriptionally regulated by multiple miRNAs (let-7c, miR-200b, miR-222, miR-424, and others) targeting its 3'-UTR, with protein stability additionally controlled through ATRAP/USP14-mediated deubiquitination and LIN28B-dependent mRNA stabilization; in development, Pbx3 is essential for medullary respiratory circuit function and dorsal spinal cord interneuron specification, while in leukemia PBX3 cooperates with MEIS1 (without requiring a HOX cofactor) to drive AML and maintain leukemia stem cells, and its aberrant expression is regulated epigenetically by elevated H3K79me2 and suppressed type I interferon signalling."},"narrative":{"mechanistic_narrative":"PBX3 is a TALE-class homeodomain transcription factor that assembles hetero-oligomeric DNA-binding complexes with homeodomain partners to control developmental and oncogenic transcriptional programmes [PMID:1682799, PMID:25911551]. It is highly homologous to PBX1 and is alternatively spliced into isoforms with distinct partner-binding properties; canonical PBX3A/B engage PREP1 and MEIS proteins, whereas leukemia-favored isoforms lose these interactions [PMID:1682799, PMID:11579467]. In development, Pbx3 partners with the metaHox factor Rnx (Tlx3) to support medullary respiratory neuron function, with loss causing fatal neonatal respiratory failure [PMID:15466398], and is required caudal to the hindbrain for correct specification and positioning of dorsal horn interneurons [PMID:18155191]; it also directly binds an intronic SHH cis-regulatory element to repress SHH transcription, acting opposite to PBX1 at the same element [PMID:40397886]. In leukemia, PBX3 is a selective HOXA9 cofactor whose depletion blocks MLL-fusion transformation, and PBX3/MEIS1 co-expression transforms hematopoietic progenitors and drives AML even without ectopic HOX by re-activating endogenous Hoxa genes [PMID:23264595, PMID:26747896]; mechanistically, PBX3 binds and stabilizes MEIS1 against ubiquitin-proteasome degradation while also inducing MEIS1 transcription and forming high-affinity Hoxa9/Meis1/Pbx3 DNA complexes [PMID:25911551]. PBX3 sustains leukemia stem cells, and its locus is epigenetically activated through elevated H3K79me2, while it suppresses type I interferon response genes during AML progression [PMID:28411381, PMID:30214626, PMID:40108441]. Across solid tumors PBX3 acts as a sequence-specific promoter-binding regulator that activates metabolic and oncogenic genes (G6PD, HMGCR, CA9) and represses tumor-suppressive genes (p53, TET2), thereby reprogramming metabolism and survival [PMID:37781025, PMID:40508020, PMID:40048803, PMID:33526870, PMID:39668567]. Its abundance is set post-transcriptionally by multiple 3'-UTR-targeting miRNAs and by RNA-binding/stability and deubiquitination pathways (DDX54, LIN28B, ATRAP/USP14) [PMID:26420065, PMID:32712782, PMID:39668567, PMID:35414770].","teleology":[{"year":1991,"claim":"Established PBX3's molecular identity as a TALE-class homeodomain factor closely related to PBX1 and revealed alternative splicing generating products with distinct C-termini, the structural basis for later isoform-specific functions.","evidence":"Molecular cloning, sequence analysis, and Northern blot","pmids":["1682799"],"confidence":"High","gaps":["No DNA-binding partners or target genes identified at this stage","Functional consequences of the two isoforms not tested"]},{"year":2001,"claim":"Defined that alternative splicing controls partner specificity, with novel isoforms (PBX3C/D) failing to bind PREP1 and binding MEIS only weakly, linking isoform choice to normal versus leukemic contexts.","evidence":"RT-PCR isoform identification and co-immunoprecipitation interaction assays","pmids":["11579467"],"confidence":"Medium","gaps":["Functional transcriptional output of each isoform not measured","Mechanism driving isoform switching in leukemia unknown"]},{"year":2004,"claim":"Demonstrated an essential developmental role: Pbx3 partners with Rnx/Tlx3 to enable TALE-complex transcriptional activity required for medullary respiratory circuit function.","evidence":"Pbx3-knockout mice with respiratory phenotype plus in vitro transcription and DNA-binding complex assays","pmids":["15466398"],"confidence":"High","gaps":["Direct target genes of the Pbx3/Rnx complex not identified","Whether the same complex operates outside the medulla untested"]},{"year":2004,"claim":"Showed PBX3 is regulated post-transcriptionally and as a partner stabilizer, with retinoic acid extending its protein half-life and decreasing proteasomal PBX degradation in association with MEIS.","evidence":"P19 differentiation model with cycloheximide chase, half-life assay, and MEIS co-IP","pmids":["15095411"],"confidence":"Medium","gaps":["E3 ligase mediating PBX degradation not identified","Direct versus indirect RA effect on PBX3 transcription unresolved"]},{"year":2007,"claim":"Extended the developmental requirement to spinal cord, showing Pbx3 controls specification and positioning of dorsal horn glutamatergic interneurons.","evidence":"Conditional knockout mouse with immunohistochemistry and neuroanatomical marker analysis","pmids":["18155191"],"confidence":"High","gaps":["Transcriptional targets driving interneuron identity not defined","Partner factors in this context not identified"]},{"year":2012,"claim":"Identified PBX3 as a selective, non-redundant HOXA9 cofactor in leukemogenesis, distinguishing it from PBX1/PBX2 and nominating the HOX-PBX interface as a therapeutic target.","evidence":"shRNA depletion, retroviral co-expression, in vitro transformation, mouse leukemia model, and HXR9 peptide disruption","pmids":["23264595"],"confidence":"High","gaps":["Genome-wide PBX3/HOXA9 target loci not mapped here","Structural basis of PBX3 selectivity over PBX1/2 not defined"]},{"year":2015,"claim":"Resolved the mechanism of PBX3-MEIS1 cooperation: PBX3 binding stabilizes otherwise degradation-prone MEIS1, induces its transcription, and forms high-affinity Hoxa9/Meis1/Pbx3 DNA complexes.","evidence":"Deletion mapping, co-IP, MG132 proteasome inhibition, half-life measurement, in vitro DNA-complex assembly, and transplantation assays","pmids":["25911551"],"confidence":"High","gaps":["E3 ligase targeting MEIS1 not identified","Whether PBX3 stabilizes other partners similarly untested"]},{"year":2015,"claim":"Showed PBX3 is a hub of post-transcriptional control and a driver of cancer stemness, repressed cooperatively by multiple 3'-UTR miRNAs and required for hepatocellular tumor-initiating cell programmes.","evidence":"miRNA gain/loss, luciferase 3'-UTR reporters, shRNA knockdown with rescue, and TIC functional and expression profiling","pmids":["26420065"],"confidence":"High","gaps":["Direct versus indirect regulation of CACNA2D1/EpCAM/SOX2/NOTCH3 not all distinguished","Cofactor requirements in HCC TICs not defined"]},{"year":2016,"claim":"Demonstrated PBX3/MEIS1 co-expression alone, without ectopic HOX, transforms progenitors and recapitulates the MLL-fusion core transcriptome by re-activating endogenous Hoxa genes.","evidence":"Retroviral co-expression, transformation and AML mouse models, expression profiling, and interface-disruption mutants","pmids":["26747896"],"confidence":"High","gaps":["How PBX3/MEIS1 induce endogenous Hoxa transcription mechanistically not resolved","Direct genomic binding sites not mapped"]},{"year":2017,"claim":"Linked PBX3 to leukemia stem cell maintenance and to its own epigenetic activation, with CRISPR deletion reducing LSC capacity and aberrant H3K79me2 gain at the Pbx3 locus.","evidence":"CRISPR/Cas9 deletion, AML transplantation, flow cytometry LSC analysis, and ChIP-seq/qPCR of histone marks","pmids":["28411381"],"confidence":"High","gaps":["Causal writer of H3K79me2 at Pbx3 not functionally tested here","Downstream LSC survival effectors not defined"]},{"year":2014,"claim":"In solid tumors, established PBX3 as a pro-migratory/invasive factor acting in part through MAPK/ERK activation.","evidence":"Forced expression/knockdown with migration and invasion assays and p-ERK1/2 immunoblot","pmids":["25561793"],"confidence":"Medium","gaps":["Direct transcriptional targets in CRC migration not identified","Whether ERK activation is direct or transcriptionally relayed unknown"]},{"year":2016,"claim":"Connected PBX3 to EMT-driven invasion in gastric cancer via AKT activation and MMP-9 induction.","evidence":"Gain/loss-of-function with EMT and p-AKT immunoblots, gelatin zymography, and xenografts","pmids":["27900025"],"confidence":"Medium","gaps":["Direct promoter targets among EMT genes not shown","Mechanism of AKT activation not defined"]},{"year":2018,"claim":"Positioned PBX3 downstream of WNT/SNAIL/ZEB1 via miR-200, integrating it into EMT regulatory circuitry in colorectal cancer.","evidence":"Reporter assays, transcriptomics, miRNA manipulation, siRNA knockdown, and in situ hybridization","pmids":["29391352"],"confidence":"Medium","gaps":["Direct miR-200 targeting of PBX3 in this context vs indirect not fully resolved","PBX3 effector genes for EMT not mapped"]},{"year":2018,"claim":"Defined a PBX3-MEK/ERK/c-Myc-LIN28-let-7 positive feedback loop driving glioblastoma mesenchymal transition.","evidence":"ChIP, dual-luciferase reporter, shRNA/overexpression, orthotopic model, and TGFbeta stimulation","pmids":["30016974"],"confidence":"Medium","gaps":["Quantitative contribution of each loop node not dissected","Generalizability beyond GBM untested"]},{"year":2020,"claim":"Identified RNA-stability feedback regulating PBX3 mRNA, with PBX3 activating lncRNA SNHG10 which recruits DDX54 to stabilize PBX3 transcripts.","evidence":"ChIP at the SNHG10 promoter, luciferase reporter, RIP, and RNA pull-down","pmids":["32712782"],"confidence":"Medium","gaps":["DDX54 binding site on PBX3 mRNA not mapped","Stoichiometry/kinetics of the feedback loop unknown"]},{"year":2021,"claim":"Showed PBX3 directly represses the p53 promoter to lower p21 and enable proliferation, establishing a direct tumor-suppressor-repression mechanism.","evidence":"ChIP at the p53 promoter, luciferase reporter, siRNA knockdown, and cell-cycle/apoptosis assays","pmids":["33526870"],"confidence":"Medium","gaps":["Cofactors enabling repression not identified","Direct binding motif within p53 promoter not defined"]},{"year":2021,"claim":"Connected PBX3 to leptin/STAT3-driven endocrine therapy resistance through FGFR1 transactivation requiring the MTA1-HDAC2 complex.","evidence":"PDX, STAT3 inhibition, gain/loss-of-function, microarray, and co-IP of PBX3-MTA1-HDAC2","pmids":["33608482"],"confidence":"Medium","gaps":["Direct PBX3 binding at FGFR1 not shown by ChIP here","Whether MTA1-HDAC2 association is direct unresolved"]},{"year":2021,"claim":"Implicated PBX3 in non-cancer pathology, directly activating TOP2A to regulate mast cell DNA damage, senescence, and parthanatos in allergic rhinitis.","evidence":"ChIP at the TOP2A promoter, shRNA knockdown, mouse AR model, and mitochondrial assays","pmids":["42006311"],"confidence":"Medium","gaps":["Upstream regulator of PBX3 in mast cells not defined","Direct binding motif not characterized"]},{"year":2021,"claim":"Placed Pbx3 downstream of purinergic P2X7 signaling in MLL-rearranged AML, accounting for P2X7's pro-leukemic and LSC-promoting effects.","evidence":"shRNA knockdown, AML mouse and PDX models, and P2X7 antagonist treatment","pmids":["32165482"],"confidence":"Medium","gaps":["Mechanism linking P2X7 to Pbx3 transcription not defined","Direct versus indirect upregulation unresolved"]},{"year":2022,"claim":"Extended purinergic control to P2X1, showing ATP-P2X1 signaling upregulates PBX3 which transactivates BCAT1 to maintain leukemia-initiating cell fate.","evidence":"P2X1 deletion AML model, phospho-site mutagenesis, expression analysis, ChIP of PBX3 at BCAT1, and antagonist treatment","pmids":["36418376"],"confidence":"Medium","gaps":["Signaling intermediates between P2X1 and PBX3 not mapped","Metabolic consequence of BCAT1 induction not fully quantified"]},{"year":2022,"claim":"Defined a deubiquitination-based stabilization mechanism in which ATRAP directs USP14 to deubiquitinate and stabilize PBX3 protein, activating AKT/mTOR.","evidence":"Co-IP of ATRAP-PBX3 and USP14-PBX3, ubiquitination and stability assays, and functional assays","pmids":["35414770"],"confidence":"Medium","gaps":["E3 ligase counteracting USP14 not identified","Ubiquitination sites on PBX3 not mapped"]},{"year":2022,"claim":"Reported PBX3 as a transcriptional activator of lncRNA DLG1-AS1 in triple-negative breast cancer.","evidence":"ChIP at the DLG1-AS1 promoter, luciferase reporter, and TNBC functional assays","pmids":["35592389"],"confidence":"Low","gaps":["ChIP-only without mutagenesis or reconstitution","Downstream consequence of DLG1-AS1 induction not defined"]},{"year":2023,"claim":"Showed PBX3 directly activates G6PD to fuel the pentose phosphate pathway, increasing NADPH/nucleotide output and lowering ROS to support tumorigenesis.","evidence":"ChIP at the G6PD promoter, luciferase reporter, metabolic assays, and xenografts","pmids":["37781025"],"confidence":"Medium","gaps":["Partner factors at the G6PD promoter not identified","Tissue specificity of this metabolic axis untested"]},{"year":2024,"claim":"Identified an mRNA-stability input from PHAX/LIN28B feeding into PBX3 protein, which directly represses TET2 to promote esophageal cancer proliferation and block apoptosis/autophagy.","evidence":"Co-IP of PHAX-LIN28B, mRNA stability assay, ChIP at TET2 promoter, luciferase reporter, and mouse tumor model","pmids":["39668567"],"confidence":"Medium","gaps":["LIN28B binding element on PBX3 mRNA not mapped","Repressive cofactors at TET2 not identified"]},{"year":2025,"claim":"Established a developmental repressive role at SHH, with PBX3 binding the intronic SFE1 element to repress SHH transcription, directly opposing PBX1 at the same element.","evidence":"RCAS overexpression/knockdown in chick, ChIP-seq, ATAC-seq, luciferase reporter, and in ovo electroporation","pmids":["40397886"],"confidence":"High","gaps":["Molecular basis of PBX3 vs PBX1 opposite activity at SFE1 not defined","Partner specificity at this element not resolved"]},{"year":2025,"claim":"Linked PBX3 to immune evasion in AML by suppressing type I interferon response genes, partially counteracting IFN-induced leukemic differentiation.","evidence":"CRISPR-mediated MLL-AF9 translocation model, in vivo progression, IFNalpha treatment, and expression analysis","pmids":["40108441"],"confidence":"Medium","gaps":["Direct PBX3 targets among IFN-response genes not mapped","Mechanism of IFN suppression not defined"]},{"year":2025,"claim":"Added an m6A input controlling PBX3, with METTL3 modifying PBX3 mRNA and PBX3 directly activating CA9 to suppress ferroptosis in esophageal squamous carcinoma.","evidence":"MeRIP of PBX3 mRNA, ChIP at the CA9 promoter, luciferase reporter, ferroptosis assays, and xenograft","pmids":["40048803"],"confidence":"Medium","gaps":["m6A reader mediating PBX3 upregulation not identified","Generality of CA9/ferroptosis axis untested"]},{"year":null,"claim":"How PBX3 selects between transcriptional activation and repression at different promoters, and which partners and chromatin contexts determine this switch genome-wide, remains unresolved.","evidence":"No discovery in the timeline maps PBX3's full genomic occupancy or defines the determinants of its activator-versus-repressor mode.","pmids":[],"confidence":"Low","gaps":["No comprehensive genome-wide PBX3 binding atlas across tissues","Structural basis of isoform- and partner-dependent activity undefined","Determinants of activation vs repression at direct targets unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[1,14,15,16,22,23,31]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[6,14,15,16,23]},{"term_id":"GO:0140313","term_label":"molecular sequestering activity","supporting_discovery_ids":[6]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[6,23]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[14,15,16,23,31]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[1,4,23]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[5,8,11]}],"complexes":["Hoxa9/Meis1/Pbx3 DNA-binding complex","Pbx3/Rnx(Tlx3) TALE complex","PBX3-MTA1-HDAC2 complex"],"partners":["MEIS1","HOXA9","PREP1","TLX3","MTA1","HDAC2","USP14"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P40426","full_name":"Pre-B-cell leukemia transcription factor 3","aliases":["Homeobox protein PBX3"],"length_aa":434,"mass_kda":47.2,"function":"Transcriptional activator that binds the sequence 5'-ATCAATCAA-3'","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/P40426/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PBX3","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PBX3","total_profiled":1310},"omim":[{"mim_id":"603099","title":"1-@ACYLGLYCEROL-3-PHOSPHATE O-ACYLTRANSFERASE 1; AGPAT1","url":"https://www.omim.org/entry/603099"},{"mim_id":"602575","title":"LIM HOMEOBOX TRANSCRIPTION FACTOR 1, BETA; LMX1B","url":"https://www.omim.org/entry/602575"},{"mim_id":"602100","title":"PBX/KNOTTED 1 HOMEOBOX 1; PKNOX1","url":"https://www.omim.org/entry/602100"},{"mim_id":"190198","title":"NOTCH RECEPTOR 1; NOTCH1","url":"https://www.omim.org/entry/190198"},{"mim_id":"176312","title":"PRE-B-CELL LEUKEMIA TRANSCRIPTION FACTOR 3; PBX3","url":"https://www.omim.org/entry/176312"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Nuclear bodies","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"parathyroid gland","ntpm":144.0}],"url":"https://www.proteinatlas.org/search/PBX3"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P40426","domains":[{"cath_id":"-","chopping":"105-119_144-236","consensus_level":"high","plddt":89.8344,"start":105,"end":236},{"cath_id":"1.10.10.60","chopping":"243-320","consensus_level":"high","plddt":93.2828,"start":243,"end":320}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P40426","model_url":"https://alphafold.ebi.ac.uk/files/AF-P40426-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P40426-F1-predicted_aligned_error_v6.png","plddt_mean":69.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PBX3","jax_strain_url":"https://www.jax.org/strain/search?query=PBX3"},"sequence":{"accession":"P40426","fasta_url":"https://rest.uniprot.org/uniprotkb/P40426.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P40426/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P40426"}},"corpus_meta":[{"pmid":"1682799","id":"PMC_1682799","title":"PBX2 and PBX3, new homeobox genes with extensive homology to the human proto-oncogene PBX1.","date":"1991","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/1682799","citation_count":272,"is_preprint":false},{"pmid":"21984339","id":"PMC_21984339","title":"Let-7c functions as a metastasis suppressor by targeting MMP11 and PBX3 in colorectal cancer.","date":"2011","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21984339","citation_count":134,"is_preprint":false},{"pmid":"23264595","id":"PMC_23264595","title":"PBX3 is an important cofactor of HOXA9 in leukemogenesis.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/23264595","citation_count":118,"is_preprint":false},{"pmid":"32487167","id":"PMC_32487167","title":"Circular RNA circCORO1C promotes laryngeal squamous cell carcinoma progression by modulating the let-7c-5p/PBX3 axis.","date":"2020","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32487167","citation_count":106,"is_preprint":false},{"pmid":"25231231","id":"PMC_25231231","title":"EWSR1-PBX3: a novel gene fusion in myoepithelial tumors.","date":"2014","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25231231","citation_count":78,"is_preprint":false},{"pmid":"15466398","id":"PMC_15466398","title":"Pbx3 deficiency results in central hypoventilation.","date":"2004","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15466398","citation_count":70,"is_preprint":false},{"pmid":"26420065","id":"PMC_26420065","title":"PBX3 is targeted by multiple miRNAs and is essential for liver tumour-initiating cells.","date":"2015","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/26420065","citation_count":64,"is_preprint":false},{"pmid":"25911551","id":"PMC_25911551","title":"Pbx3 and Meis1 cooperate through multiple mechanisms to support Hox-induced murine leukemia.","date":"2015","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/25911551","citation_count":63,"is_preprint":false},{"pmid":"25561793","id":"PMC_25561793","title":"PBX3 promotes migration and invasion of colorectal cancer cells via activation of MAPK/ERK signaling pathway.","date":"2014","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/25561793","citation_count":61,"is_preprint":false},{"pmid":"21548940","id":"PMC_21548940","title":"Regulation of PBX3 expression by androgen and Let-7d in prostate cancer.","date":"2011","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21548940","citation_count":60,"is_preprint":false},{"pmid":"18461604","id":"PMC_18461604","title":"Expression of FOXP2 in the developing monkey forebrain: comparison with the expression of the genes FOXP1, PBX3, and MEIS2.","date":"2008","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/18461604","citation_count":59,"is_preprint":false},{"pmid":"26747896","id":"PMC_26747896","title":"PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease.","date":"2016","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/26747896","citation_count":57,"is_preprint":false},{"pmid":"28111340","id":"PMC_28111340","title":"MicroRNA-144-3p suppresses gastric cancer progression by inhibiting epithelial-to-mesenchymal transition through targeting PBX3.","date":"2017","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/28111340","citation_count":55,"is_preprint":false},{"pmid":"23161775","id":"PMC_23161775","title":"MicroRNA profiling in pediatric pilocytic astrocytoma reveals biologically relevant targets, including PBX3, NFIB, and METAP2.","date":"2012","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23161775","citation_count":48,"is_preprint":false},{"pmid":"35509064","id":"PMC_35509064","title":"EIF4A3-induced circTOLLIP promotes the progression of hepatocellular carcinoma via the miR-516a-5p/PBX3/EMT pathway.","date":"2022","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/35509064","citation_count":46,"is_preprint":false},{"pmid":"27285759","id":"PMC_27285759","title":"MicroRNA-33a-3p suppresses cell migration and invasion by directly targeting PBX3 in human hepatocellular carcinoma.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27285759","citation_count":46,"is_preprint":false},{"pmid":"16434237","id":"PMC_16434237","title":"Spatio-temporal expression of Pbx3 during mouse organogenesis.","date":"2006","source":"Gene expression patterns : GEP","url":"https://pubmed.ncbi.nlm.nih.gov/16434237","citation_count":45,"is_preprint":false},{"pmid":"29391352","id":"PMC_29391352","title":"PBX3 Is Part of an EMT Regulatory Network and Indicates Poor Outcome in Colorectal Cancer.","date":"2018","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/29391352","citation_count":45,"is_preprint":false},{"pmid":"15095411","id":"PMC_15095411","title":"Retinoic acid regulates the expression of PBX1, PBX2, and PBX3 in P19 cells both transcriptionally and post-translationally.","date":"2004","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15095411","citation_count":44,"is_preprint":false},{"pmid":"24375258","id":"PMC_24375258","title":"PBX3 is overexpressed in gastric cancer and regulates cell proliferation.","date":"2013","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24375258","citation_count":41,"is_preprint":false},{"pmid":"32069812","id":"PMC_32069812","title":"PBX3 in Cancer.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/32069812","citation_count":40,"is_preprint":false},{"pmid":"31135487","id":"PMC_31135487","title":"Cutaneous Syncytial Myoepithelioma Is Characterized by Recurrent EWSR1-PBX3 Fusions.","date":"2019","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31135487","citation_count":40,"is_preprint":false},{"pmid":"28411381","id":"PMC_28411381","title":"PBX3 is essential for leukemia stem cell maintenance in MLL-rearranged leukemia.","date":"2017","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28411381","citation_count":37,"is_preprint":false},{"pmid":"27273830","id":"PMC_27273830","title":"PBX3 is a putative biomarker of aggressive prostate cancer.","date":"2016","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/27273830","citation_count":36,"is_preprint":false},{"pmid":"30214626","id":"PMC_30214626","title":"Inactivation of PBX3 and HOXA9 by down-regulating H3K79 methylation represses NPM1-mutated leukemic cell survival.","date":"2018","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/30214626","citation_count":35,"is_preprint":false},{"pmid":"27900025","id":"PMC_27900025","title":"PBX3 promotes gastric cancer invasion and metastasis by inducing epithelial-mesenchymal transition.","date":"2016","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/27900025","citation_count":35,"is_preprint":false},{"pmid":"23539541","id":"PMC_23539541","title":"HOXA/PBX3 knockdown impairs growth and sensitizes cytogenetically normal acute myeloid leukemia cells to chemotherapy.","date":"2013","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/23539541","citation_count":35,"is_preprint":false},{"pmid":"32165482","id":"PMC_32165482","title":"P2X7 promotes the progression of MLL-AF9 induced acute myeloid leukemia by upregulation of Pbx3.","date":"2021","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/32165482","citation_count":34,"is_preprint":false},{"pmid":"30016974","id":"PMC_30016974","title":"PBX3/MEK/ERK1/2/LIN28/let-7b positive feedback loop enhances mesenchymal phenotype to promote glioblastoma migration and invasion.","date":"2018","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/30016974","citation_count":34,"is_preprint":false},{"pmid":"33389498","id":"PMC_33389498","title":"LncRNA H19 suppresses pyroptosis of cardiomyocytes to attenuate myocardial infarction in a PBX3/CYP1B1-dependent manner.","date":"2021","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33389498","citation_count":32,"is_preprint":false},{"pmid":"28934982","id":"PMC_28934982","title":"MiR-320 inhibits the growth of glioma cells through downregulating PBX3.","date":"2017","source":"Biological research","url":"https://pubmed.ncbi.nlm.nih.gov/28934982","citation_count":31,"is_preprint":false},{"pmid":"11579467","id":"PMC_11579467","title":"Novel alternative PBX3 isoforms in leukemia cells with distinct interaction specificities.","date":"2001","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11579467","citation_count":29,"is_preprint":false},{"pmid":"32519740","id":"PMC_32519740","title":"LncRNA HOXA-AS2 promotes the progression of prostate cancer via targeting miR-509-3p/PBX3 axis.","date":"2020","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/32519740","citation_count":28,"is_preprint":false},{"pmid":"31518383","id":"PMC_31518383","title":"miR-129-5p suppresses proliferation, migration, and induces apoptosis in pancreatic cancer cells by targeting PBX3.","date":"2019","source":"Acta biochimica et biophysica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/31518383","citation_count":27,"is_preprint":false},{"pmid":"32325080","id":"PMC_32325080","title":"Long non-coding RNA HNF1A-AS1 upregulates OTX1 to enhance angiogenesis in colon cancer via the binding of transcription factor PBX3.","date":"2020","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/32325080","citation_count":27,"is_preprint":false},{"pmid":"30355621","id":"PMC_30355621","title":"Functional testing of a human PBX3 variant in zebrafish reveals a potential modifier role in congenital heart defects.","date":"2018","source":"Disease models & mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/30355621","citation_count":26,"is_preprint":false},{"pmid":"32712782","id":"PMC_32712782","title":"SNHG10/DDX54/PBX3 Feedback Loop Contributes to Gastric Cancer Cell Growth.","date":"2020","source":"Digestive diseases and sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32712782","citation_count":25,"is_preprint":false},{"pmid":"28042507","id":"PMC_28042507","title":"MicroRNA-497 suppresses cell proliferation and induces apoptosis through targeting PBX3 in human multiple myeloma.","date":"2016","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/28042507","citation_count":24,"is_preprint":false},{"pmid":"35414770","id":"PMC_35414770","title":"USF1-ATRAP-PBX3 Axis Promote Breast Cancer Glycolysis and Malignant Phenotype by Activating AKT/mTOR Signaling.","date":"2022","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35414770","citation_count":23,"is_preprint":false},{"pmid":"30765768","id":"PMC_30765768","title":"miR-302a inhibits human HepG2 and SMMC-7721 cells proliferation and promotes apoptosis by targeting MAP3K2 and PBX3.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30765768","citation_count":23,"is_preprint":false},{"pmid":"18155191","id":"PMC_18155191","title":"Pbx3 is required for normal locomotion and dorsal horn development.","date":"2007","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/18155191","citation_count":23,"is_preprint":false},{"pmid":"34006845","id":"PMC_34006845","title":"LncRNA CD27-AS1 promotes acute myeloid leukemia progression through the miR-224-5p/PBX3 signaling circuit.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/34006845","citation_count":23,"is_preprint":false},{"pmid":"33526870","id":"PMC_33526870","title":"The transcription factor PBX3 promotes tumor cell growth through transcriptional suppression of the tumor suppressor p53.","date":"2021","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/33526870","citation_count":22,"is_preprint":false},{"pmid":"29670366","id":"PMC_29670366","title":"miR-495 inhibits proliferation, migration, and invasion and induces apoptosis via inhibiting PBX3 in melanoma cells.","date":"2018","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/29670366","citation_count":22,"is_preprint":false},{"pmid":"37781025","id":"PMC_37781025","title":"PBX3 promotes pentose phosphate pathway and colorectal cancer progression by enhancing G6PD expression.","date":"2023","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37781025","citation_count":21,"is_preprint":false},{"pmid":"25875009","id":"PMC_25875009","title":"Fusion of the genes EWSR1 and PBX3 in retroperitoneal leiomyoma with t(9;22)(q33;q12).","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25875009","citation_count":19,"is_preprint":false},{"pmid":"35646117","id":"PMC_35646117","title":"CircNRIP1 Exerts Oncogenic Functions in Papillary Thyroid Carcinoma by Sponging miR-653-5p and Regulating PBX3 Expression.","date":"2022","source":"Journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35646117","citation_count":16,"is_preprint":false},{"pmid":"33215418","id":"PMC_33215418","title":"Knockdown of lncRNA HCG11 suppresses cell progression in ovarian cancer by modulating miR-144-3p/PBX3.","date":"2020","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33215418","citation_count":16,"is_preprint":false},{"pmid":"31662823","id":"PMC_31662823","title":"MicroRNA-320a suppresses tumor progression by targeting PBX3 in gastric cancer and is downregulated by DNA methylation.","date":"2019","source":"World journal of gastrointestinal oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31662823","citation_count":16,"is_preprint":false},{"pmid":"32157373","id":"PMC_32157373","title":"MiR-4458/human antigen R (HuR) modulates PBX3 mRNA stability in melanoma tumorigenesis.","date":"2020","source":"Archives of dermatological research","url":"https://pubmed.ncbi.nlm.nih.gov/32157373","citation_count":15,"is_preprint":false},{"pmid":"34001137","id":"PMC_34001137","title":"Circular RNA circHECTD1 prevents Diosbulbin-B-sensitivity via miR-137/PBX3 axis in gastric cancer.","date":"2021","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/34001137","citation_count":15,"is_preprint":false},{"pmid":"33968209","id":"PMC_33968209","title":"HOXA11-AS induces cisplatin resistance by modulating the microRNA-98/PBX3 axis in nasopharyngeal carcinoma.","date":"2021","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/33968209","citation_count":15,"is_preprint":false},{"pmid":"30834570","id":"PMC_30834570","title":"EWSR1-PBX3 gene fusion in cutaneous syncytial myoepithelioma.","date":"2019","source":"Journal of cutaneous pathology","url":"https://pubmed.ncbi.nlm.nih.gov/30834570","citation_count":14,"is_preprint":false},{"pmid":"32449803","id":"PMC_32449803","title":"Downregulation of lncRNA-HEIH curbs esophageal squamous cell carcinoma progression by modulating miR-4458/PBX3.","date":"2020","source":"Thoracic cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32449803","citation_count":14,"is_preprint":false},{"pmid":"8088777","id":"PMC_8088777","title":"Genetic linkage analysis of the Ak1, Col5a1, Epb7.2, Fpgs, Grp78, Pbx3, and Notch1 genes in the region of mouse chromosome 2 homologous to human chromosome 9q.","date":"1994","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8088777","citation_count":14,"is_preprint":false},{"pmid":"32047817","id":"PMC_32047817","title":"PBX3 Promotes Tumor Growth and Angiogenesis via Activation of AT1R/VEGFR2 Pathway in Papillary Thyroid Carcinoma.","date":"2020","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/32047817","citation_count":13,"is_preprint":false},{"pmid":"35142595","id":"PMC_35142595","title":"Long non-coding RNA DSCAM-AS1 promotes pancreatic cancer progression via regulating the miR-136-5p/PBX3 axis.","date":"2022","source":"Bioengineered","url":"https://pubmed.ncbi.nlm.nih.gov/35142595","citation_count":13,"is_preprint":false},{"pmid":"30605259","id":"PMC_30605259","title":"EWSR1-PBX3 fused myoepithelioma arising in metatarsal bone: Case report and review of the literature.","date":"2019","source":"Pathology international","url":"https://pubmed.ncbi.nlm.nih.gov/30605259","citation_count":13,"is_preprint":false},{"pmid":"36418376","id":"PMC_36418376","title":"P2X1 enhances leukemogenesis through PBX3-BCAT1 pathways.","date":"2022","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/36418376","citation_count":12,"is_preprint":false},{"pmid":"33099955","id":"PMC_33099955","title":"MiR-320a inhibits malignant phenotype of melanoma cells via targeting PBX3.","date":"2020","source":"Journal of B.U.ON. : official journal of the Balkan Union of Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33099955","citation_count":12,"is_preprint":false},{"pmid":"33608482","id":"PMC_33608482","title":"Leptin-elicited PBX3 confers letrozole resistance in breast cancer.","date":"2021","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33608482","citation_count":11,"is_preprint":false},{"pmid":"25266220","id":"PMC_25266220","title":"CBFB-MYH11 hypomethylation signature and PBX3 differential methylation revealed by targeted bisulfite sequencing in patients with acute myeloid leukemia.","date":"2014","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25266220","citation_count":11,"is_preprint":false},{"pmid":"36699282","id":"PMC_36699282","title":"Circ-ATIC regulates esophageal squamous cell carcinoma growth and metastasis through miR-1294/PBX3 pathway.","date":"2023","source":"Heliyon","url":"https://pubmed.ncbi.nlm.nih.gov/36699282","citation_count":10,"is_preprint":false},{"pmid":"33015777","id":"PMC_33015777","title":"MiR-144 inhibits colorectal cancer cell migration and invasion by regulating PBX3.","date":"2020","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33015777","citation_count":10,"is_preprint":false},{"pmid":"35592389","id":"PMC_35592389","title":"PBX3-activated DLG1-AS1 can promote the proliferation, invasion, and migration of TNBC cells by sponging miR-16-5p.","date":"2022","source":"Molecular therapy oncolytics","url":"https://pubmed.ncbi.nlm.nih.gov/35592389","citation_count":9,"is_preprint":false},{"pmid":"36004524","id":"PMC_36004524","title":"Circ_0003489 facilitates multiple myeloma progression by targeting miR-433-3p/PBX3 axis.","date":"2022","source":"Hematology (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/36004524","citation_count":9,"is_preprint":false},{"pmid":"34742151","id":"PMC_34742151","title":"Circular RNA circ_0032962 promotes trophoblast cell progression as ceRNA to target PBX3 via sponging miR-326 in preeclampsia.","date":"2021","source":"Reproductive biology","url":"https://pubmed.ncbi.nlm.nih.gov/34742151","citation_count":8,"is_preprint":false},{"pmid":"37129228","id":"PMC_37129228","title":"An intraosseous myoepithelial carcinoma with a EWSR1::PBX3 fusion.","date":"2023","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37129228","citation_count":8,"is_preprint":false},{"pmid":"32096159","id":"PMC_32096159","title":"Long noncoding RNA NORAD promotes the progression of retinoblastoma by sponging miR-136-5p/PBX3 axis.","date":"2020","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32096159","citation_count":8,"is_preprint":false},{"pmid":"38763423","id":"PMC_38763423","title":"Myoepithelial Tumors of Bone With EWSR1::PBX3 Fusion: A Spectrum From Benign to Malignant.","date":"2024","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/38763423","citation_count":7,"is_preprint":false},{"pmid":"33846790","id":"PMC_33846790","title":"Long non‑coding RNA LINC00460 serves as a potential biomarker and oncogene via regulation of the miR‑320b/PBX3 axis in acute myeloid leukemia.","date":"2021","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/33846790","citation_count":7,"is_preprint":false},{"pmid":"36753664","id":"PMC_36753664","title":"ERN1 dependent impact of glucose and glutamine deprivations on PBX3, PBXIP1, PAX6, MEIS1, and MEIS2 genes expression in U87 glioma cells.","date":"2023","source":"Endocrine regulations","url":"https://pubmed.ncbi.nlm.nih.gov/36753664","citation_count":6,"is_preprint":false},{"pmid":"38528641","id":"PMC_38528641","title":"Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax.","date":"2024","source":"Clinical epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/38528641","citation_count":6,"is_preprint":false},{"pmid":"33155190","id":"PMC_33155190","title":"MiR-655-3p inhibits growth and invasiveness of trophoblasts via targeting PBX3 and thus deteriorates preeclampsia.","date":"2020","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33155190","citation_count":6,"is_preprint":false},{"pmid":"25394196","id":"PMC_25394196","title":"The miR-302 cluster transcriptionally regulated by POUV, SOX and STAT5B controls the undifferentiated state through the post-transcriptional repression of PBX3 and E2F7 in early chick development.","date":"2014","source":"Molecular reproduction and development","url":"https://pubmed.ncbi.nlm.nih.gov/25394196","citation_count":6,"is_preprint":false},{"pmid":"32374004","id":"PMC_32374004","title":"Long noncoding RNA NORAD promotes the progression of retinoblastoma by sponging miR 136-5p/PBX3 axis.","date":"2020","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32374004","citation_count":6,"is_preprint":false},{"pmid":"37730964","id":"PMC_37730964","title":"Exosomal circKIAA1797 Regulates Cell Progression and Glycolysis by Targeting miR-4429/PBX3 Pathway in Gastric Cancer.","date":"2023","source":"Biochemical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/37730964","citation_count":5,"is_preprint":false},{"pmid":"32714042","id":"PMC_32714042","title":"MG132 inhibits the expression of PBX3 through miRNAs by targeting Argonaute2 in hepatoma cells.","date":"2020","source":"Saudi journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32714042","citation_count":5,"is_preprint":false},{"pmid":"37300672","id":"PMC_37300672","title":"LncRNA LINC00885 promotes bladder cancer progression by targeting the miR-98-5p/PBX3 axis.","date":"2023","source":"Cellular and molecular biology (Noisy-le-Grand, France)","url":"https://pubmed.ncbi.nlm.nih.gov/37300672","citation_count":4,"is_preprint":false},{"pmid":"39668567","id":"PMC_39668567","title":"PHAX enhanced LIN28B-mediated PBX3 mRNA stability to promote esophageal cancer development.","date":"2024","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/39668567","citation_count":4,"is_preprint":false},{"pmid":"35342419","id":"PMC_35342419","title":"circNBPF10/miR-224 Axis Regulates PBX3 to Promote the Malignant Progression of Lung Cancer.","date":"2022","source":"Journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35342419","citation_count":4,"is_preprint":false},{"pmid":"40397886","id":"PMC_40397886","title":"PBX1 and PBX3 transcription factors regulate SHH expression in the Frontonasal Ectodermal Zone through complementary mechanisms.","date":"2025","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/40397886","citation_count":3,"is_preprint":false},{"pmid":"40508020","id":"PMC_40508020","title":"PBX3-HMGCR Axis Promotes Hepatocellular Carcinoma Progression Through Enhancing De Novo Cholesterol Biosynthesis.","date":"2025","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/40508020","citation_count":3,"is_preprint":false},{"pmid":"36086865","id":"PMC_36086865","title":"Long noncoding RNA-LINC00478 promotes the progression of clear cell renal cell carcinoma through PBX3.","date":"2022","source":"Journal of biochemical and molecular toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/36086865","citation_count":3,"is_preprint":false},{"pmid":"34854109","id":"PMC_34854109","title":"A case of cutaneous syncytial myoepithelioma with extensive adipocytic metaplasia: Usefulness of EWSR1-PBX3 gene fusion analysis.","date":"2022","source":"Journal of cutaneous pathology","url":"https://pubmed.ncbi.nlm.nih.gov/34854109","citation_count":3,"is_preprint":false},{"pmid":"40048803","id":"PMC_40048803","title":"METTL3 enhances esophageal squamous cell carcinoma progression by suppressing ferroptosis through the PBX3/CA9 cascade.","date":"2025","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/40048803","citation_count":2,"is_preprint":false},{"pmid":"39239553","id":"PMC_39239553","title":"Mitochondrial ATP Synthesis and Proton Transport Synergistically Mitigate Oligodendrocyte Progenitor Cell Dysfunction Following Transient Middle Cerebral Artery Occlusion via the Pbx3/Dguok/Kif21b Signaling Pathway.","date":"2024","source":"International journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39239553","citation_count":1,"is_preprint":false},{"pmid":"38895322","id":"PMC_38895322","title":"PBX1 and PBX3 transcription factors regulate SHH expression in the Frontonasal Ectodermal Zone through complementary mechanisms.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/38895322","citation_count":0,"is_preprint":false},{"pmid":"41662636","id":"PMC_41662636","title":"Review Article: Decoding the Role of PBX3 in Cancer: Molecular Mechanisms and Therapeutic Strategies.","date":"2025","source":"Critical reviews in oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/41662636","citation_count":0,"is_preprint":false},{"pmid":"42006311","id":"PMC_42006311","title":"PBX3 regulates mast cell parthanatos via TOP2A mediated DNA damage in allergic rhinitis.","date":"2026","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/42006311","citation_count":0,"is_preprint":false},{"pmid":"40821037","id":"PMC_40821037","title":"LncRNA HCP5 promotes the progression of gastric cancer through the miR-526b/PBX3 axis.","date":"2025","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/40821037","citation_count":0,"is_preprint":false},{"pmid":"40108441","id":"PMC_40108441","title":"Pbx3-mediated suppression of type I interferon response contributes to leukemia progression driven by MLL-AF9.","date":"2025","source":"Cancer gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/40108441","citation_count":0,"is_preprint":false},{"pmid":"34522465","id":"PMC_34522465","title":"MicroRNA-497 suppresses cell proliferation and induces apoptosis through targeting PBX3 in human multiple myeloma [Retraction].","date":"2021","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/34522465","citation_count":0,"is_preprint":false},{"pmid":"35949221","id":"PMC_35949221","title":"Correction to \"MicroRNA-320a suppresses tumor progression by targeting PBX3 in gastric cancer and is downregulated by DNA methylation\".","date":"2022","source":"World journal of gastrointestinal oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35949221","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.11.11.687613","title":"WNT inhibition primes the transcriptional landscape of mesoderm to initiate a phased ventricular cardiomyocyte specification programme","date":"2025-11-12","source":"bioRxiv","url":"https://doi.org/10.1101/2025.11.11.687613","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.10.13.681683","title":"Co-targeting menin and LSD1 dismantles oncogenic programs and restores differentiation in MLL-rearranged AML","date":"2025-10-15","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.13.681683","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.05.20.654944","title":"Physical principles of phase-separation action on chromatin looping associated to pathogenic gene activation","date":"2025-05-23","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.20.654944","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51522,"output_tokens":8160,"usd":0.138483,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17645,"output_tokens":7401,"usd":0.136625,"stage2_stop_reason":"end_turn"},"total_usd":0.275108,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1991,\n      \"finding\": \"PBX3 is a TALE-class homeodomain transcription factor with 94% identity to PBX1 over 266 amino acids spanning and flanking the homeodomain. PBX3 mRNA is alternatively spliced to yield two translation products with different carboxy termini, a feature shared with PBX1 but not PBX2.\",\n      \"method\": \"Molecular cloning, sequence analysis, Northern blot (alternative splicing)\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — primary molecular characterization with sequence analysis and alternative splicing demonstrated directly; foundational paper replicated across subsequent literature\",\n      \"pmids\": [\"1682799\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Pbx3-deficient mice die within hours of birth from central respiratory failure due to abnormal inspiratory neuron activity in the medulla oblongata. Pbx3 forms a DNA-binding complex with the metaHox transcription factor Rnx (Tlx3), and in the absence of Pbx3, Rnx's ability to enhance transcription in vitro as part of a TALE-protein complex is abolished, though Rnx expression itself is unaffected.\",\n      \"method\": \"Knockout mouse (Pbx3-deficient), in vitro transcription assay, co-immunoprecipitation / DNA-binding complex formation\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function mouse model with defined respiratory phenotype plus in vitro transcriptional assay demonstrating Pbx3-dependent Rnx activity; multiple orthogonal methods\",\n      \"pmids\": [\"15466398\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Two novel PBX3 isoforms (PBX3C and PBX3D) generated by alternative splicing are unable to interact with the PBX-interacting factor PREP1 and interact only weakly with MEIS proteins, in contrast to canonical PBX3A/B isoforms. PBX3C expression is favored in leukemia cells whereas PBX3D predominates in normal cells.\",\n      \"method\": \"RT-PCR (isoform identification), co-immunoprecipitation / interaction assays (functional binding studies)\",\n      \"journal\": \"Genes, chromosomes & cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding assays showing differential interaction specificity of isoforms; single lab, two methods\",\n      \"pmids\": [\"11579467\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Retinoic acid increases PBX3 mRNA levels as a secondary (not primary) transcriptional response requiring new protein synthesis, and retinoic acid treatment also significantly extends PBX3 protein half-life. PBX proteins associate with RA-dependent increased MEIS protein levels, and RA may decrease proteasome-dependent PBX protein degradation.\",\n      \"method\": \"P19 cell differentiation model, cycloheximide chase (mRNA stability), protein half-life assay, co-immunoprecipitation with MEIS proteins\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct measurement of mRNA stability and protein half-life, plus co-IP with MEIS; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"15095411\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Conditional loss of Pbx3 caudal to the hindbrain leads to progressive locomotion and posture deficits, reduced dorsal horn size, and loss of calbindin-, PKC-gamma-, and calretinin-expressing neurons in laminae I–III. In embryonic dorsal horn, Pbx3 is expressed in a subset of glutamatergic neurons; its absence causes incorrect specification of some glutamatergic neurons and abnormal positioning of Meis+ glutamatergic neurons.\",\n      \"method\": \"Conditional knockout mouse, immunohistochemistry, cell counting, neuroanatomical analysis\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with detailed cellular phenotype and neuronal specification defects characterized by multiple markers\",\n      \"pmids\": [\"18155191\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"PBX3 (but not PBX1 or PBX2) acts as a critical cofactor of HOXA9 in leukemogenesis: shRNA depletion of Pbx3 significantly inhibits MLL-fusion-mediated cell transformation, and co-expression of PBX3 with HOXA9 synergistically promotes cell transformation in vitro and AML in vivo. The small peptide HXR9, which disrupts HOX-PBX interactions, selectively kills leukemic cells with HOXA/PBX3 overexpression.\",\n      \"method\": \"shRNA knockdown, retroviral overexpression, in vitro transformation assay, mouse leukemia model, HXR9 peptide treatment\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (KD, OE, in vivo, peptide disruption); replicated in subsequent studies\",\n      \"pmids\": [\"23264595\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Pbx3 and Meis1 must dimerize to support Hox-induced leukemia. In the absence of Pbx3, Meis1 protein is highly unstable and undergoes ubiquitin-proteasome-mediated degradation via a motif coinciding with the Pbx-binding domain; binding to Pbx3 or deletion of this motif prolongs Meis1 half-life. Additionally, Pbx3 overexpression induces endogenous Meis1 transcription. Meis1 binding to Pbx3 is required to form high-affinity DNA/Hoxa9/Meis1/Pbx3 complexes in vitro.\",\n      \"method\": \"Deletion analysis, co-immunoprecipitation, ubiquitin-proteasome inhibitor assay (MG132), protein half-life measurement, in vitro DNA-binding complex formation, colony-forming assay, transplantation assay\",\n      \"journal\": \"Haematologica\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — mechanistic dissection of Meis1 stability via Pbx3 binding with reconstituted DNA complex and multiple biochemical and functional methods\",\n      \"pmids\": [\"25911551\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PBX3 is targeted synergistically by let-7c, miR-200b, miR-222, and miR-424 at its 3'-UTR, and is both sufficient and necessary for the acquisition and maintenance of HCC tumor-initiating cell (TIC) properties. PBX3 drives a transcriptional programme activating CACNA2D1, EpCAM, SOX2, and NOTCH3 expression in HCC TICs.\",\n      \"method\": \"miRNA overexpression/inhibition, luciferase 3'-UTR reporter assay, shRNA knockdown, TIC functional assays (sphere formation, tumorigenicity), rescue experiments, gene expression profiling\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple miRNA validated by luciferase assay, functional necessity shown by KD and rescue, transcriptional targets identified; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"26420065\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Co-expression of PBX3 and MEIS1 (without ectopic HOX) is sufficient to transform normal mouse hematopoietic stem/progenitor cells and cause AML in vivo. PBX3/MEIS1 overexpression recapitulates the MLL-fusion core transcriptome including upregulation of endogenous Hoxa genes. Disruption of the MEIS1-PBX3 binding interface abolishes transformation and HOX gene upregulation.\",\n      \"method\": \"Retroviral co-expression, in vitro transformation assay, mouse AML model, gene expression profiling, binding-interface disruption mutants\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vitro transformation plus in vivo AML with transcriptomic validation and mechanistic disruption of PBX3/MEIS1 interaction; multiple orthogonal methods\",\n      \"pmids\": [\"26747896\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"PBX3 promotes migration and invasion of colorectal cancer cells partially through activation of the MAPK/ERK signaling pathway, as evidenced by upregulation of phosphorylated ERK1/2 upon PBX3 overexpression.\",\n      \"method\": \"Forced expression and shRNA knockdown, wound-healing assay, Boyden chamber assay, Western blot (p-ERK1/2)\",\n      \"journal\": \"World journal of gastroenterology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct KD/OE with defined signaling readout (p-ERK1/2); single lab, two orthogonal functional and biochemical methods\",\n      \"pmids\": [\"25561793\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PBX3 promotes gastric cancer invasion and metastasis by inducing EMT (increased N-cadherin and vimentin, decreased E-cadherin) and activating AKT (increased p-AKT Ser473) and MMP-9 activity.\",\n      \"method\": \"Overexpression/knockdown, Western blot (EMT markers, p-AKT), gelatin zymography (MMP-9), nude mouse xenograft\",\n      \"journal\": \"Oncology letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple downstream pathway readouts (EMT, AKT, MMP-9) in gain- and loss-of-function experiments; single lab\",\n      \"pmids\": [\"27900025\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Pbx3 deletion via CRISPR/Cas9 in MLL-AF9 AML mouse model significantly prolongs survival and decreases leukemia burden by reducing leukemia stem cell (LSC) capacity and promoting LSC apoptosis. ChIP-seq/qPCR in MLL-rearranged mouse models revealed aberrant epigenetic modifications with increased H3K79me2 and decreased H3K9me3 and H3K27me3 at Pbx3 loci in LSCs.\",\n      \"method\": \"CRISPR/Cas9 deletion, mouse AML model transplantation, flow cytometry (LSC analysis), ChIP-seq/qPCR (histone modifications)\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — CRISPR KO with defined LSC phenotype plus epigenomic profiling; multiple orthogonal methods\",\n      \"pmids\": [\"28411381\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"PBX3 expression in colorectal cancer is induced by WNT pathway activation and by EMT transcription factors SNAIL and ZEB1, with these effects mediated indirectly through microRNA miR-200. PBX3 is required for a full EMT phenotype in colon cancer cells.\",\n      \"method\": \"Reporter assays, transcriptomic analysis, miRNA manipulation, siRNA knockdown, in situ hybridization\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis experiments placing PBX3 downstream of WNT/SNAIL/ZEB1 via miR-200, with functional EMT phenotype; single lab\",\n      \"pmids\": [\"29391352\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"PBX3 promotes GBM mesenchymal transition through activation of MEK/ERK1/2 signaling, leading to increased c-Myc-dependent LIN28 expression. LIN28 then inhibits let-7b biogenesis; let-7b suppresses PBX3 by targeting its 3'-UTR, forming a positive feedback loop. ChIP experiments confirmed PBX3-driven transcriptional activation of LIN28 via MEK/ERK/c-Myc.\",\n      \"method\": \"Western blot, ChIP, dual-luciferase reporter assay, shRNA/overexpression, orthotopic mouse model, TGFβ stimulation\",\n      \"journal\": \"Journal of experimental & clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus luciferase plus rescue experiments in single lab demonstrating feedback loop mechanism\",\n      \"pmids\": [\"30016974\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PBX3 binds to the p53 promoter and suppresses its transcriptional activity, thereby reducing p21 expression and enabling tumor cell proliferation. PBX3 silencing induces p21 expression and increases apoptosis in colorectal cancer cells.\",\n      \"method\": \"ChIP (PBX3 binding to p53 promoter), luciferase reporter assay, siRNA knockdown, cell cycle/apoptosis analysis\",\n      \"journal\": \"Acta pharmacologica Sinica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus reporter assay plus functional KD readout; single lab, two orthogonal molecular methods\",\n      \"pmids\": [\"33526870\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PBX3 directly binds to the G6PD promoter and activates its transcription, stimulating the pentose phosphate pathway (PPP), enhancing NADPH and nucleotide production, decreasing intracellular ROS, and promoting tumorigenic potential in vitro and in vivo.\",\n      \"method\": \"ChIP (PBX3 binding to G6PD promoter), luciferase reporter assay, metabolic assays (NADPH, nucleotide, ROS), xenograft model\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and reporter assay confirm direct promoter binding, metabolic phenotype confirmed; single lab\",\n      \"pmids\": [\"37781025\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PBX3 directly binds to the HMGCR promoter (-167/-151 region) and increases its transcriptional activity, thereby upregulating cholesterol biosynthesis in HCC cells and enhancing tumorigenic potential in vivo.\",\n      \"method\": \"ChIP (PBX3 binding to HMGCR promoter), luciferase reporter assay, cholesterol biosynthesis measurement, xenograft model\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and reporter assay confirm direct promoter binding with metabolic and tumor phenotype; single lab\",\n      \"pmids\": [\"40508020\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PBX3 directly binds to the TOP2A promoter to activate its transcription, regulating mast cell DNA damage, senescence, mitochondrial function, and parthanatos in allergic rhinitis. PBX3 knockdown significantly alleviates AR symptoms in mice.\",\n      \"method\": \"ChIP (PBX3 binding to TOP2A promoter), shRNA knockdown, mouse AR model, mitochondrial membrane potential assay\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP confirms direct promoter binding with functional mouse model readout; single lab\",\n      \"pmids\": [\"42006311\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"lncRNA H19 inhibits CYP1B1 expression by regulating PBX3, which directly binds to the CYP1B1 promoter to control its activity. This H19/PBX3/CYP1B1 axis modulates cardiomyocyte pyroptosis during myocardial infarction.\",\n      \"method\": \"RIP, dual-luciferase reporter assay (H19-PBX3-CYP1B1 axis), overexpression/knockdown, MI rat model\",\n      \"journal\": \"Molecular and cellular biochemistry\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — reporter assay and RIP in single lab; mechanistic role of PBX3 as transcriptional repressor of CYP1B1 suggested but not confirmed by direct ChIP of PBX3 at CYP1B1 promoter\",\n      \"pmids\": [\"33389498\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PBX3 acts as a transcriptional activator of the lncRNA SNHG10 promoter in gastric cancer cells. SNHG10 in turn stabilizes PBX3 mRNA through recruiting the RNA-binding protein DDX54, forming a positive feedback loop. DDX54 was shown by RIP and RNA pull-down to bind both SNHG10 and PBX3 mRNA.\",\n      \"method\": \"ChIP (PBX3 binding to SNHG10 promoter), luciferase reporter assay, RIP, RNA pull-down (DDX54-SNHG10-PBX3 mRNA interaction)\",\n      \"journal\": \"Digestive diseases and sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP, luciferase, RIP, and RNA pull-down in single lab; multiple orthogonal molecular methods\",\n      \"pmids\": [\"32712782\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Leptin activates PBX3 expression in a STAT3-dependent manner in breast cancer cells. PBX3 confers letrozole resistance via transactivation of FGFR1 signaling, and this requires interaction with the MTA1-HDAC2 complex.\",\n      \"method\": \"Patient-derived xenograft, pharmacological STAT3 inhibition, gain/loss-of-function, microarray profiling, co-immunoprecipitation (PBX3-MTA1-HDAC2 complex)\",\n      \"journal\": \"Endocrine-related cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — STAT3-dependent regulation and co-IP with MTA1-HDAC2 complex with functional resistance phenotype; single lab, multiple methods\",\n      \"pmids\": [\"33608482\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ATRAP directs USP14-mediated deubiquitination and stabilization of PBX3 protein, preventing its degradation. USF1 transcriptionally activates ATRAP expression, creating a USF1/ATRAP/PBX3 axis that activates AKT/mTOR signaling in breast cancer.\",\n      \"method\": \"Co-immunoprecipitation (ATRAP-PBX3, USP14-PBX3), ubiquitination assay, protein stability assay, microarray analysis, functional assays\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical deubiquitination mechanism with co-IP and functional validation; single lab\",\n      \"pmids\": [\"35414770\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PHAX stabilizes PBX3 mRNA through interaction with LIN28B (RNA-binding protein). PBX3 then directly binds to the TET2 promoter and transcriptionally represses it, promoting esophageal cancer cell proliferation and suppressing apoptosis and autophagy.\",\n      \"method\": \"Co-immunoprecipitation (PHAX-LIN28B), mRNA stability assay, ChIP (PBX3 at TET2 promoter), luciferase reporter assay, KD/OE functional assays, mouse tumor model\",\n      \"journal\": \"Cancer science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus ChIP plus reporter with functional mouse model; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"39668567\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PBX3 directly binds a cis-regulatory element (SFE1) within intron 1 of SHH and represses its transcriptional activity in the chick Frontonasal Ectodermal Zone; this is opposite to PBX1, which activates transcription through the same element. Overexpressing PBX3 decreases SHH expression, while reducing PBX3 induces ectopic SHH expression.\",\n      \"method\": \"RCAS viral overexpression/knockdown in chick embryos, ChIP-seq (PBX3/PBX1 binding), ATAC-seq, luciferase reporter assay, in ovo electroporation of reporter constructs\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — ChIP-seq binding validated by luciferase and in ovo reporter plus gain/loss-of-function with SHH phenotype; multiple orthogonal methods in single study\",\n      \"pmids\": [\"40397886\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"P2X7 receptor activation upregulates Pbx3 expression in MLL-rearranged AML cells, and the P2X7-Pbx3 pathway accounts for P2X7's pro-leukemic effects on cell proliferation and leukemia stem cell levels.\",\n      \"method\": \"shRNA knockdown, mouse AML model, patient-derived xenograft, P2X7 antagonist treatment, nude mouse xenograft\",\n      \"journal\": \"Haematologica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacological P2X7 manipulation with defined Pbx3-dependent leukemic phenotype; single lab, multiple in vivo models\",\n      \"pmids\": [\"32165482\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"P2X1 phosphorylation at S387 and T389 is required for its leukemia-promoting effects. ATP-P2X1-mediated signaling upregulates PBX3, which transactivates BCAT1 to maintain leukemia-initiating cell (LIC) fates.\",\n      \"method\": \"P2X1 deletion (mouse AML model), phospho-site mutagenesis, gene expression analysis, ChIP (PBX3 transactivation of BCAT1), P2X1 antagonist treatment\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO, phospho-site mutagenesis, and transcriptional target analysis (BCAT1); single lab\",\n      \"pmids\": [\"36418376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Pbx3 suppresses type I interferon response genes during MLL-AF9-driven AML progression in vivo. Leukemia progression is associated with Pbx3 upregulation in progenitor cells and downregulation of IFN-response genes; enhancing IFN signaling (IFNα) induces leukemic cell differentiation, and this is partially overcome by Pbx3 activity.\",\n      \"method\": \"CRISPR-mediated chromosomal translocation (MLL-AF9 model), in vivo leukemia progression assay, IFNα treatment, gene expression analysis\",\n      \"journal\": \"Cancer gene therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR mouse model with defined transcriptional phenotype (IFN suppression) and IFNα rescue; single lab\",\n      \"pmids\": [\"40108441\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"A human PBX3 variant (p.A136V), introduced into the homologous zebrafish pbx4 gene (p.A131V) via CRISPR-Cas9 precise genome editing, acts as a genetic modifier of cardiac morphogenesis: homozygous pbx4 p.A131V zebrafish are viable but the variant enhances the embryonic cardiac defect caused by loss of the Hand2 cardiac specification factor.\",\n      \"method\": \"CRISPR-Cas9 precision genome editing (single-stranded oligodeoxynucleotide knock-in), zebrafish genetic modifier assay (pbx4 p.A131V × hand2 loss-of-function)\",\n      \"journal\": \"Disease models & mechanisms\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — rigorous precision genome editing with epistasis readout in zebrafish; single lab, well-controlled functional genetics\",\n      \"pmids\": [\"30355621\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"PBX3 differential DNA methylation correlates with PBX3 gene expression in AML patients. In inv(16)/CBFB-MYH11 AML, targeted bisulfite sequencing revealed a hypomethylation pattern associated with genes upregulated in this subtype.\",\n      \"method\": \"Targeted bisulfite sequencing, 454 bisulfite pyrosequencing, microarray gene expression profiling (correlation of methylation with expression)\",\n      \"journal\": \"Journal of hematology & oncology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — correlative methylation-expression analysis without functional manipulation of methylation at the PBX3 locus\",\n      \"pmids\": [\"25266220\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Inactivation of PBX3 and HOXA9 by reducing H3K79 methylation (via DOT1L inhibitor EPZ5676) promotes apoptosis in NPM1-mutated (NPMc+) leukemic cells. NPMc+ overexpression increases H3K79me2/me3 at the HOXA9 gene locus (but not the PBX3 locus); PBX3 expression is positively regulated by HOXA9; and reduction of either PBX3 or HOXA9 causes NPMc+ cell apoptosis.\",\n      \"method\": \"ChIP-seq (H3K79 methylation at HOXA9/PBX3 loci), siRNA knockdown, DOT1L inhibitor (EPZ5676) treatment, NPMc+ overexpression/depletion, apoptosis assay\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq with pharmacological and genetic validation; single lab, multiple methods\",\n      \"pmids\": [\"30214626\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PBX3 acts as a transcriptional activator of the lncRNA DLG1-AS1 in triple-negative breast cancer (TNBC) cells, as demonstrated by ChIP assay showing PBX3 binding to the DLG1-AS1 promoter.\",\n      \"method\": \"ChIP (PBX3 at DLG1-AS1 promoter), luciferase reporter assay, functional TNBC cell assays\",\n      \"journal\": \"Molecular therapy oncolytics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, ChIP only without mutagenesis or reconstitution\",\n      \"pmids\": [\"35592389\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"METTL3 promotes m6A modification of PBX3 mRNA, leading to its upregulation. PBX3 in turn binds the CA9 promoter and activates its transcription, suppressing ferroptosis in esophageal squamous cell carcinoma.\",\n      \"method\": \"MeRIP assay (m6A on PBX3 mRNA), ChIP (PBX3 at CA9 promoter), luciferase reporter assay, ferroptosis assays (ROS, MDA, Fe2+), KD/OE functional assays, xenograft\",\n      \"journal\": \"Pathology, research and practice\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — MeRIP plus ChIP plus reporter assay with functional ferroptosis phenotype; single lab, multiple methods\",\n      \"pmids\": [\"40048803\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PBX3 is a TALE-class homeodomain transcription factor that forms hetero-oligomeric DNA-binding complexes with HOX proteins (especially HOXA9), MEIS1, and other homeodomain partners to regulate developmental gene expression and oncogenic transcriptional programmes; it directly binds promoters of target genes (SHH, G6PD, HMGCR, TOP2A, p53, TET2, CA9) to activate or repress transcription, stabilizes partner proteins (e.g., MEIS1 via preventing ubiquitin-proteasome degradation), and is itself post-transcriptionally regulated by multiple miRNAs (let-7c, miR-200b, miR-222, miR-424, and others) targeting its 3'-UTR, with protein stability additionally controlled through ATRAP/USP14-mediated deubiquitination and LIN28B-dependent mRNA stabilization; in development, Pbx3 is essential for medullary respiratory circuit function and dorsal spinal cord interneuron specification, while in leukemia PBX3 cooperates with MEIS1 (without requiring a HOX cofactor) to drive AML and maintain leukemia stem cells, and its aberrant expression is regulated epigenetically by elevated H3K79me2 and suppressed type I interferon signalling.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"PBX3 is a TALE-class homeodomain transcription factor that assembles hetero-oligomeric DNA-binding complexes with homeodomain partners to control developmental and oncogenic transcriptional programmes [#0, #6]. It is highly homologous to PBX1 and is alternatively spliced into isoforms with distinct partner-binding properties; canonical PBX3A/B engage PREP1 and MEIS proteins, whereas leukemia-favored isoforms lose these interactions [#0, #2]. In development, Pbx3 partners with the metaHox factor Rnx (Tlx3) to support medullary respiratory neuron function, with loss causing fatal neonatal respiratory failure [#1], and is required caudal to the hindbrain for correct specification and positioning of dorsal horn interneurons [#4]; it also directly binds an intronic SHH cis-regulatory element to repress SHH transcription, acting opposite to PBX1 at the same element [#23]. In leukemia, PBX3 is a selective HOXA9 cofactor whose depletion blocks MLL-fusion transformation, and PBX3/MEIS1 co-expression transforms hematopoietic progenitors and drives AML even without ectopic HOX by re-activating endogenous Hoxa genes [#5, #8]; mechanistically, PBX3 binds and stabilizes MEIS1 against ubiquitin-proteasome degradation while also inducing MEIS1 transcription and forming high-affinity Hoxa9/Meis1/Pbx3 DNA complexes [#6]. PBX3 sustains leukemia stem cells, and its locus is epigenetically activated through elevated H3K79me2, while it suppresses type I interferon response genes during AML progression [#11, #29, #26]. Across solid tumors PBX3 acts as a sequence-specific promoter-binding regulator that activates metabolic and oncogenic genes (G6PD, HMGCR, CA9) and represses tumor-suppressive genes (p53, TET2), thereby reprogramming metabolism and survival [#15, #16, #31, #14, #22]. Its abundance is set post-transcriptionally by multiple 3'-UTR-targeting miRNAs and by RNA-binding/stability and deubiquitination pathways (DDX54, LIN28B, ATRAP/USP14) [#7, #19, #22, #21].\",\n  \"teleology\": [\n    {\n      \"year\": 1991,\n      \"claim\": \"Established PBX3's molecular identity as a TALE-class homeodomain factor closely related to PBX1 and revealed alternative splicing generating products with distinct C-termini, the structural basis for later isoform-specific functions.\",\n      \"evidence\": \"Molecular cloning, sequence analysis, and Northern blot\",\n      \"pmids\": [\"1682799\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No DNA-binding partners or target genes identified at this stage\", \"Functional consequences of the two isoforms not tested\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Defined that alternative splicing controls partner specificity, with novel isoforms (PBX3C/D) failing to bind PREP1 and binding MEIS only weakly, linking isoform choice to normal versus leukemic contexts.\",\n      \"evidence\": \"RT-PCR isoform identification and co-immunoprecipitation interaction assays\",\n      \"pmids\": [\"11579467\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional transcriptional output of each isoform not measured\", \"Mechanism driving isoform switching in leukemia unknown\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Demonstrated an essential developmental role: Pbx3 partners with Rnx/Tlx3 to enable TALE-complex transcriptional activity required for medullary respiratory circuit function.\",\n      \"evidence\": \"Pbx3-knockout mice with respiratory phenotype plus in vitro transcription and DNA-binding complex assays\",\n      \"pmids\": [\"15466398\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct target genes of the Pbx3/Rnx complex not identified\", \"Whether the same complex operates outside the medulla untested\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Showed PBX3 is regulated post-transcriptionally and as a partner stabilizer, with retinoic acid extending its protein half-life and decreasing proteasomal PBX degradation in association with MEIS.\",\n      \"evidence\": \"P19 differentiation model with cycloheximide chase, half-life assay, and MEIS co-IP\",\n      \"pmids\": [\"15095411\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"E3 ligase mediating PBX degradation not identified\", \"Direct versus indirect RA effect on PBX3 transcription unresolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Extended the developmental requirement to spinal cord, showing Pbx3 controls specification and positioning of dorsal horn glutamatergic interneurons.\",\n      \"evidence\": \"Conditional knockout mouse with immunohistochemistry and neuroanatomical marker analysis\",\n      \"pmids\": [\"18155191\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcriptional targets driving interneuron identity not defined\", \"Partner factors in this context not identified\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identified PBX3 as a selective, non-redundant HOXA9 cofactor in leukemogenesis, distinguishing it from PBX1/PBX2 and nominating the HOX-PBX interface as a therapeutic target.\",\n      \"evidence\": \"shRNA depletion, retroviral co-expression, in vitro transformation, mouse leukemia model, and HXR9 peptide disruption\",\n      \"pmids\": [\"23264595\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genome-wide PBX3/HOXA9 target loci not mapped here\", \"Structural basis of PBX3 selectivity over PBX1/2 not defined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Resolved the mechanism of PBX3-MEIS1 cooperation: PBX3 binding stabilizes otherwise degradation-prone MEIS1, induces its transcription, and forms high-affinity Hoxa9/Meis1/Pbx3 DNA complexes.\",\n      \"evidence\": \"Deletion mapping, co-IP, MG132 proteasome inhibition, half-life measurement, in vitro DNA-complex assembly, and transplantation assays\",\n      \"pmids\": [\"25911551\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ligase targeting MEIS1 not identified\", \"Whether PBX3 stabilizes other partners similarly untested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showed PBX3 is a hub of post-transcriptional control and a driver of cancer stemness, repressed cooperatively by multiple 3'-UTR miRNAs and required for hepatocellular tumor-initiating cell programmes.\",\n      \"evidence\": \"miRNA gain/loss, luciferase 3'-UTR reporters, shRNA knockdown with rescue, and TIC functional and expression profiling\",\n      \"pmids\": [\"26420065\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct versus indirect regulation of CACNA2D1/EpCAM/SOX2/NOTCH3 not all distinguished\", \"Cofactor requirements in HCC TICs not defined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrated PBX3/MEIS1 co-expression alone, without ectopic HOX, transforms progenitors and recapitulates the MLL-fusion core transcriptome by re-activating endogenous Hoxa genes.\",\n      \"evidence\": \"Retroviral co-expression, transformation and AML mouse models, expression profiling, and interface-disruption mutants\",\n      \"pmids\": [\"26747896\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How PBX3/MEIS1 induce endogenous Hoxa transcription mechanistically not resolved\", \"Direct genomic binding sites not mapped\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Linked PBX3 to leukemia stem cell maintenance and to its own epigenetic activation, with CRISPR deletion reducing LSC capacity and aberrant H3K79me2 gain at the Pbx3 locus.\",\n      \"evidence\": \"CRISPR/Cas9 deletion, AML transplantation, flow cytometry LSC analysis, and ChIP-seq/qPCR of histone marks\",\n      \"pmids\": [\"28411381\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Causal writer of H3K79me2 at Pbx3 not functionally tested here\", \"Downstream LSC survival effectors not defined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"In solid tumors, established PBX3 as a pro-migratory/invasive factor acting in part through MAPK/ERK activation.\",\n      \"evidence\": \"Forced expression/knockdown with migration and invasion assays and p-ERK1/2 immunoblot\",\n      \"pmids\": [\"25561793\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct transcriptional targets in CRC migration not identified\", \"Whether ERK activation is direct or transcriptionally relayed unknown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Connected PBX3 to EMT-driven invasion in gastric cancer via AKT activation and MMP-9 induction.\",\n      \"evidence\": \"Gain/loss-of-function with EMT and p-AKT immunoblots, gelatin zymography, and xenografts\",\n      \"pmids\": [\"27900025\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct promoter targets among EMT genes not shown\", \"Mechanism of AKT activation not defined\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Positioned PBX3 downstream of WNT/SNAIL/ZEB1 via miR-200, integrating it into EMT regulatory circuitry in colorectal cancer.\",\n      \"evidence\": \"Reporter assays, transcriptomics, miRNA manipulation, siRNA knockdown, and in situ hybridization\",\n      \"pmids\": [\"29391352\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct miR-200 targeting of PBX3 in this context vs indirect not fully resolved\", \"PBX3 effector genes for EMT not mapped\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined a PBX3-MEK/ERK/c-Myc-LIN28-let-7 positive feedback loop driving glioblastoma mesenchymal transition.\",\n      \"evidence\": \"ChIP, dual-luciferase reporter, shRNA/overexpression, orthotopic model, and TGFbeta stimulation\",\n      \"pmids\": [\"30016974\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Quantitative contribution of each loop node not dissected\", \"Generalizability beyond GBM untested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified RNA-stability feedback regulating PBX3 mRNA, with PBX3 activating lncRNA SNHG10 which recruits DDX54 to stabilize PBX3 transcripts.\",\n      \"evidence\": \"ChIP at the SNHG10 promoter, luciferase reporter, RIP, and RNA pull-down\",\n      \"pmids\": [\"32712782\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"DDX54 binding site on PBX3 mRNA not mapped\", \"Stoichiometry/kinetics of the feedback loop unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed PBX3 directly represses the p53 promoter to lower p21 and enable proliferation, establishing a direct tumor-suppressor-repression mechanism.\",\n      \"evidence\": \"ChIP at the p53 promoter, luciferase reporter, siRNA knockdown, and cell-cycle/apoptosis assays\",\n      \"pmids\": [\"33526870\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cofactors enabling repression not identified\", \"Direct binding motif within p53 promoter not defined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Connected PBX3 to leptin/STAT3-driven endocrine therapy resistance through FGFR1 transactivation requiring the MTA1-HDAC2 complex.\",\n      \"evidence\": \"PDX, STAT3 inhibition, gain/loss-of-function, microarray, and co-IP of PBX3-MTA1-HDAC2\",\n      \"pmids\": [\"33608482\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct PBX3 binding at FGFR1 not shown by ChIP here\", \"Whether MTA1-HDAC2 association is direct unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Implicated PBX3 in non-cancer pathology, directly activating TOP2A to regulate mast cell DNA damage, senescence, and parthanatos in allergic rhinitis.\",\n      \"evidence\": \"ChIP at the TOP2A promoter, shRNA knockdown, mouse AR model, and mitochondrial assays\",\n      \"pmids\": [\"42006311\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Upstream regulator of PBX3 in mast cells not defined\", \"Direct binding motif not characterized\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Placed Pbx3 downstream of purinergic P2X7 signaling in MLL-rearranged AML, accounting for P2X7's pro-leukemic and LSC-promoting effects.\",\n      \"evidence\": \"shRNA knockdown, AML mouse and PDX models, and P2X7 antagonist treatment\",\n      \"pmids\": [\"32165482\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking P2X7 to Pbx3 transcription not defined\", \"Direct versus indirect upregulation unresolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Extended purinergic control to P2X1, showing ATP-P2X1 signaling upregulates PBX3 which transactivates BCAT1 to maintain leukemia-initiating cell fate.\",\n      \"evidence\": \"P2X1 deletion AML model, phospho-site mutagenesis, expression analysis, ChIP of PBX3 at BCAT1, and antagonist treatment\",\n      \"pmids\": [\"36418376\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Signaling intermediates between P2X1 and PBX3 not mapped\", \"Metabolic consequence of BCAT1 induction not fully quantified\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined a deubiquitination-based stabilization mechanism in which ATRAP directs USP14 to deubiquitinate and stabilize PBX3 protein, activating AKT/mTOR.\",\n      \"evidence\": \"Co-IP of ATRAP-PBX3 and USP14-PBX3, ubiquitination and stability assays, and functional assays\",\n      \"pmids\": [\"35414770\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"E3 ligase counteracting USP14 not identified\", \"Ubiquitination sites on PBX3 not mapped\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Reported PBX3 as a transcriptional activator of lncRNA DLG1-AS1 in triple-negative breast cancer.\",\n      \"evidence\": \"ChIP at the DLG1-AS1 promoter, luciferase reporter, and TNBC functional assays\",\n      \"pmids\": [\"35592389\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"ChIP-only without mutagenesis or reconstitution\", \"Downstream consequence of DLG1-AS1 induction not defined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed PBX3 directly activates G6PD to fuel the pentose phosphate pathway, increasing NADPH/nucleotide output and lowering ROS to support tumorigenesis.\",\n      \"evidence\": \"ChIP at the G6PD promoter, luciferase reporter, metabolic assays, and xenografts\",\n      \"pmids\": [\"37781025\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Partner factors at the G6PD promoter not identified\", \"Tissue specificity of this metabolic axis untested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identified an mRNA-stability input from PHAX/LIN28B feeding into PBX3 protein, which directly represses TET2 to promote esophageal cancer proliferation and block apoptosis/autophagy.\",\n      \"evidence\": \"Co-IP of PHAX-LIN28B, mRNA stability assay, ChIP at TET2 promoter, luciferase reporter, and mouse tumor model\",\n      \"pmids\": [\"39668567\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"LIN28B binding element on PBX3 mRNA not mapped\", \"Repressive cofactors at TET2 not identified\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Established a developmental repressive role at SHH, with PBX3 binding the intronic SFE1 element to repress SHH transcription, directly opposing PBX1 at the same element.\",\n      \"evidence\": \"RCAS overexpression/knockdown in chick, ChIP-seq, ATAC-seq, luciferase reporter, and in ovo electroporation\",\n      \"pmids\": [\"40397886\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of PBX3 vs PBX1 opposite activity at SFE1 not defined\", \"Partner specificity at this element not resolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Linked PBX3 to immune evasion in AML by suppressing type I interferon response genes, partially counteracting IFN-induced leukemic differentiation.\",\n      \"evidence\": \"CRISPR-mediated MLL-AF9 translocation model, in vivo progression, IFNalpha treatment, and expression analysis\",\n      \"pmids\": [\"40108441\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct PBX3 targets among IFN-response genes not mapped\", \"Mechanism of IFN suppression not defined\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Added an m6A input controlling PBX3, with METTL3 modifying PBX3 mRNA and PBX3 directly activating CA9 to suppress ferroptosis in esophageal squamous carcinoma.\",\n      \"evidence\": \"MeRIP of PBX3 mRNA, ChIP at the CA9 promoter, luciferase reporter, ferroptosis assays, and xenograft\",\n      \"pmids\": [\"40048803\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"m6A reader mediating PBX3 upregulation not identified\", \"Generality of CA9/ferroptosis axis untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How PBX3 selects between transcriptional activation and repression at different promoters, and which partners and chromatin contexts determine this switch genome-wide, remains unresolved.\",\n      \"evidence\": \"No discovery in the timeline maps PBX3's full genomic occupancy or defines the determinants of its activator-versus-repressor mode.\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No comprehensive genome-wide PBX3 binding atlas across tissues\", \"Structural basis of isoform- and partner-dependent activity undefined\", \"Determinants of activation vs repression at direct targets unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [1, 14, 15, 16, 22, 23, 31]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [6, 14, 15, 16, 23]},\n      {\"term_id\": \"GO:0140313\", \"supporting_discovery_ids\": [6]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [6, 23]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [14, 15, 16, 23, 31]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [1, 4, 23]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [5, 8, 11]}\n    ],\n    \"complexes\": [\"Hoxa9/Meis1/Pbx3 DNA-binding complex\", \"Pbx3/Rnx(Tlx3) TALE complex\", \"PBX3-MTA1-HDAC2 complex\"],\n    \"partners\": [\"MEIS1\", \"HOXA9\", \"PREP1\", \"TLX3\", \"MTA1\", \"HDAC2\", \"USP14\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}